Effects of monoamine oxidase Type B inhibitors on motor and non-motor symptoms in Parkinson's disease: A systematic comparison of rasagiline and selegiline

Basal Ganglia

Volumn 2, Issue 4 SUPPL., 2012, Pages

  Löhle, Matthias ^a,b   Storch, Alexander ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Monoamine oxidase inhibitors; Non motor symptoms; Parkinson's disease; Pharmacotherapy; Rasagiline; Selegiline

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE; SELEGILINE; SELEGILINE ODT; TOCOPHEROL; UNCLASSIFIED DRUG; ZYDIS SELEGILINE;

AKINESIA; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COLUMBIA UNIVERSITY RATING SCALE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; HAMILTON SCALE; HUMAN; MAINTENANCE DRUG DOSE; MONOTHERAPY; MOOD DISORDER; MORNING DOSAGE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NORTHWESTERN UNIVERSITY DISABILITY SCALE; PARKINSON DISEASE; PARKINSON DISEASE QUALITY OF LIFE SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; TABLET DISINTEGRATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84872397464     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2012.06.007     Document Type: Article

References (40)

1. Parkinson J. An essay on the shaking palsy 1817, London: Sherwood, Neely, and Jones, London.
2. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 1998, 339(15):1044-1053.
3. Lopez-Munoz F., Alamo C., Juckel G., Assion H.J. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. J Clin Psychopharmacol 2007, 27(6):555-559.
4. Zetzel L., Kaplan H. Liver damage concurrent with iproniazid administration. N Engl J Med 1958, 258(24):1209-1211.
5. Spellberg M.A., Frankel J.J. Hepatic and renal damage with azotemia associated with iproniazid administration. Am J Gastroenterol 1962, 37:64-69.
6. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963, 2(7313):849-850.
7. Hutchison J.C., Kinlaw W.B. Tranylcypromine and reaction to cheese. Curr Ther Res Clin Exp 1964, 6:127-129.
8. Youdim M.B., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006, 147(Suppl 1):S287-S296.
9. Paterson I.A., Davis B.A., Durden D.A., Juorio A.V., Yu P.H., Ivy G., et al. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain. Neurochem Res 1995, 20(12):1503-1510.
10. Knoll J., Ecseri Z., Kelemen K., Nievel J., Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 1965, 155(1):154-164.
11. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972, 5:393-408.
12. Churchyard A., Mathias C.J., Boonkongchuen P., Lees A.J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 63(2):228-234.
13. Yasar S., Goldberg J.P., Goldberg S.R. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl 1996, 48:61-73.
14. Chen J.J., Swope D.M. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005, 45(8):878-894.
15. Chen J.J., Swope D.M., Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007, 29(9):1825-1849.
16. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245(4917):519-522.
17. Myllyla V.V., Sotaniemi K.A., Vuorinen J.A., Heinonen E.H. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992, 42(2):339-343.
18. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328:176-183. Parkinson Study Group.
19. Allain H., Pollak P., Neukirch H.C. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 1993, 8(Suppl 1):S36-S40.
20. Palhagen S., Heinonen E.H., Hagglund J., Kaugesaar T., Kontants H., Maki-Ikola O., et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson study group. Neurology 1998, 51(2):520-525.
21. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002, 59(12):1937-1943. Parkinson Study Group.
22. Stern M.B., Marek K.L., Friedman J., Hauser R.A., LeWitt P.A., Tarsy D., et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004, 19(8):916-923.
23. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361(13):1268-1278.
24. Rascol O., Fitzer-Attas C.J., Hauser R., Jankovic J., Lang A., Langston J.W., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011, 10(5):415-423.
25. Fox S.H., Katzenschlager R., Lim S.Y., Ravina B., Seppi K., Coelho M., et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011, 26(Suppl 3):S2-S41.
26. Jost W.H., Friede M., Schnitker J. Indirekte metaanalyse randomisierter plazebokontrollierter klinischer Studien zu Rasagilin und Selegilin in der symptomatischen Behandlung der Parkinson-Krankheit. Akt Neurol 2011, 28(05):242-252.
27. Shulman L.M., Gruber-Baldini A.L., Anderson K.E., Fishman P.S., Reich S.G., Weiner W.J. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010, 67(1):64-70.
28. Lees A.J., Shaw K.M., Kohout L.J., Stern G.M., Elsworth J.D., Sandler M., et al. Deprenyl in Parkinson's disease. Lancet 1977, 2(8042):791-795.
29. Lieberman A.N., Gopinathan G., Neophytides A., Foo S.H. Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med 1987, 87(12):646-649.
30. Golbe L.I., Lieberman A.N., Muenter M.D., Ahlskog J.E., Gopinathan G., Neophytides A.N., et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988, 11(1):45-55.
31. Clarke A., Brewer F., Johnson E.S., Mallard N., Hartig F., Taylor S., et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003, 110(11):1241-1255.
32. Waters C.H., Sethi K.D., Hauser R.A., Molho E., Bertoni J.M. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004, 19(4):426-432.
33. Ondo W.G., Sethi K.D., Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and " wearing off" symptoms. Clin Neuropharmacol 2007, 30(5):295-300.
34. Rabey J.M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000, 23(6):324-330.
35. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005, 62(2):241-248. Parkinson Study Group.
36. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365(9463):947-954.
37. Hietanen M.H. Selegiline and cognitive function in Parkinson's disease. Acta Neurol Scand 1991, 84(5):407-410.
38. Dalrymple-Alford J.C., Jamieson C.F., Donaldson I.M. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease. Clin Neuropharmacol 1995, 18(4):348-359.
39. Biglan K.M., Schwid S., Eberly S., Blindauer K., Fahn S., Goren T., et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006, 21(5):616-623.
40. Hanagasi H.A., Gurvit H., Unsalan P., Horozoglu H., Tuncer N., Feyzioglu A., et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011, 26(10):1851-1858.